BACKGROUND: Cell salvage may be used during cardiac surgery to avoid allogeneic blood transfusion. It has also been claimed to improve patient outcomes by removing debris from shed blood, which may increase the risk of stroke or neurocognitive dysfunction. In this study, we sought to determine the overall safety and efficacy of cell salvage in cardiac surgery by performing a systematic review and meta-analysis of published randomized controlled trials. METHODS: A comprehensive search was undertaken to identify all randomized trials of cell saver use during cardiac surgery. MEDLINE, Cochrane Library, EMBASE, and abstract databases were searched up to November 2008. All randomized trials comparing cell saver use and no cell saver use in cardiac surgery and reporting at least one predefined clinical outcome were included. The random effects model was used to calculate the odds ratios (OR, 95% confidence intervals [CI]) and the weighted mean differences (WMD, 95% CI) for dichotomous and continuous variables, respectively. RESULTS: Thirty-one randomized trials involving 2282 patients were included in the meta-analysis. During cardiac surgery, the use of an intraoperative cell saver reduced the rate of exposure to any allogeneic blood product (OR 0.63, 95% CI: 0.43-0.94, P ϭ 0.02) and red blood cells (OR 0.60, 95% CI: 0.39 -0.92, P ϭ 0.02) and decreased the mean volume of total allogeneic blood products transfused per patient (WMD Ϫ256 mL, 95% CI: Ϫ416 to Ϫ95 mL, P ϭ 0.002). There was no difference in hospital mortality (OR 0.65, 95% CI: 0.25-1.68, P ϭ 0.37), postoperative stroke or transient ischemia attack (OR 0.59, 95% CI: 0.20 -1.76, P ϭ 0.34), atrial fibrillation (OR 0.92, 95% CI: 0.69 -1.23, P ϭ 0.56), renal dysfunction (OR 0.86, 95% CI: 0.41-1.80, P ϭ 0.70), infection (OR 1.25, 95% CI: 0.75-2.10, P ϭ 0.39), patients requiring fresh frozen plasma (OR 1.16, 95% CI: 0.82-1.66, P ϭ 0.40), and patients requiring platelet transfusions (OR 0.90, 95% CI: 0.63-1.28, P ϭ 0.55) between cell saver and noncell saver groups. CONCLUSIONS: Current evidence suggests that the use of a cell saver reduces exposure to allogeneic blood products or red blood cell transfusion for patients undergoing cardiac surgery. Subanalyses suggest that a cell saver may be beneficial only when it is used for shed blood and/or residual blood or during the entire operative period. Processing cardiotomy suction blood with a cell saver only during cardiopulmonary bypass has no significant effect on blood conservation and increases fresh frozen plasma transfusion.
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Intraoperative salvage of RBCs using a cell-saving apparatus (cell saver, CS) is a common blood conservation strategy used during cardiac operations. Numerous published randomized controlled trials support the routine use of a CS to reduce blood transfusions. 6 -18 Furthermore, CS devices can theoretically remove lipid particles implicated in the etiology of postoperative neurocognitive dysfunction that are otherwise not removed by arterial filters used during cardiopulmonary bypass (CPB). 19 A recent survey demonstrated that up to 40% of cardiac teams regularly process cardiotomy blood with centrifugal washing. 20 While salvaging RBCs for recirculation to the patient, a CS also removes platelets and hemostatic blood factors that are concentrated in the cellwashing supernatant. Rubens et al. 21 recently reported that processing of cardiotomy blood with a CS in patients undergoing cardiac surgery resulted in an increase in postoperative bleeding and greater use of allogeneic blood products. Djaiani et al. 19 also reported that processing of cardiotomy blood with a CS resulted in an increased transfusion of fresh frozen plasma (FFP). Furthermore, a recent randomized trial by Klein et al. 22 demonstrated that the routine use of a CS does not reduce the proportion of patients exposed to allogeneic blood transfusion. These latter trials contrast with earlier trials showing reduced blood product use, and the reasons for these differences across published trials need exploration.
Trials of CS use during cardiac surgery have generally been inadequately powered to provide an adequate assessment of the risk versus benefit of this blood conservation strategy, especially for perioperative complications. The aim of this study was to determine, through systematic review with metaanalysis of all relevant randomized trials, whether intraoperative CS use (compared with no CS) reduces blood product utilization, morbidity, mortality, and resource utilization in cardiac surgical patients and whether different time periods of CS use (during CPB only versus throughout the entire operative period) is related to differences in outcomes.
METHODS

Searching for Trials
This meta-analysis of randomized trials was performed in accordance with the Quality of Reporting of Meta-analyses (QUOROM) consensus guidelines and according to a protocol that prespecified outcomes, search strategies, inclusion criteria, and statistical analyses. 23 A comprehensive search was undertaken to identify all published or unpublished randomized trials of intraoperative use of a CS versus no CS during cardiac surgery. MEDLINE, Cochrane CENTRAL, EMBASE, Current Contents, Database of abstracts of reviews of effects, NHS economic evaluation database, and International network of agencies for health technology assessment databases were searched from the date of their inception to November 2008. Search terms included cell salvage, cell saver, autotransfusion, open heart surgery, cardiac surgery, coronary artery bypass grafting, cardiopulmonary bypass, offpump, and congenital heart surgery. Tangential electronic exploration of related articles and hand searches of bibliographies, scientific meeting abstracts, and related journals were also performed.
Inclusion Criteria
Studies were included if they met each of the following criteria 1 : adult patients undergoing cardiac surgery 2 , randomized allocation to a CS group versus no CS group 3 , and reporting at least one relevant clinical or economic outcome. Blinded and unblinded studies in any language were included. CS was defined as use of an extracorporeal cell saving device, whether used during CPB only, or pre-CPB and post-CPB only, or throughout the entire operation (pre-CPB, during CPB, post-CPB). Studies were excluded if a CS was used only in the postoperative period and in trials in which the CS blood was reinfused without washing.
Data Extraction
Two authors (GYW, DB) screened abstracts and retrieved the full text to identify trials for inclusion. Additionally, information on demographics, interventions, and outcomes was extracted in duplicate. The two reviewers independently assigned each trial a Jadad quality score that evaluates randomization, blinding, and completeness of the follow-up (maximum score, 5). 24 Disagreements were resolved by consensus.
End Points
The primary outcome was defined as the number of patients requiring any blood product transfusion. Secondary outcomes included the number of patients requiring RBC, FFP, or platelets transfusion, and the mean volume of RBCs, FFP, platelets, and total blood products transfused. Other secondary outcomes included all-cause mortality, stroke, acute myocardial infarction, atrial fibrillation, renal failure, infections, postoperative neurocognitive dysfunction, reexploration for bleeding, postoperative chest tube drainage, 24-h postoperative hemoglobin (Hb) concentration, duration of mechanical lung ventilation, intensive care unit (ICU) length of stay (LOS), hospital LOS, quality of life, and hospital costs. Stroke, acute myocardial infarction, acute renal failure or dialysis, and atrial fibrillation were defined according to study authors' definitions. Infections were defined according to study authors' definitions and included both deep and superficial wound infections. We included neurocognitive dysfunction as an outcome when reported as a dichotomous variable and when cognitive tests performed were in accordance with the statement of consensus. 25 Duration of mechanical lung ventilation was measured from the end of surgery to the time of tracheal extubation. ICU and hospital LOS were measured from the end of surgery until ICU or hospital discharge, respectively. 
Statistical Analysis
Outcomes were analyzed as dichotomous (when incidence was reported) or continuous (when the mean and standard deviation were reported) variables. For dichotomous variables, odds ratios and 95% confidence intervals (OR, 95% CI) were calculated. For continuous variables, the weighted mean difference (WMD, 95% CI) was calculated. Standardized mean differences were planned for costs and QOL analyses; however, these outcomes were insufficiently reported for combined analyses. Heterogeneity was explored using I 2 . The I 2 indicates the proportion of variability among trials that cannot be attributable to chance alone; it provides an improved measure of heterogeneity among trials that is not limited by power. 26, 27 Values of I 2 higher than 50% were considered to indicate significant heterogeneity among trials.
For each outcome, the DerSimonian and Laird (random effects) model 28 was used for analysis. For subgroups analyses, a mixed effect model was used to analyze data across subgroups and to explore heterogeneity among groups. Pooled effect estimates and heterogeneity among studies were analyzed using Comprehensive Meta-Analysis version 2 software (Englewood, NJ, 2002). Statistical significance was defined as two-sided (P Ͻ 0.05) and a confidence interval that excluded the possibility of no effect. Whenever possible, data analysis was by intention to treat.
Although the primary analysis combined all types of CS, we planned to subanalyze the results to explore whether important differences could be attributed to CPB, timing of CS use, and study design. Subgroup analyses were planned a priori for surgery performed with or without CPB (off-pump versus on-pump) and for the method of CS used during operation (cardiotomy suction [CS1] versus shed and/or residual pump blood [CS2]). Cardiotomy suction subgroup (CS1) was defined as studies in which CS was only used to process cardiotomy suction blood during CPB. Shed and/or residual pump blood subgroup (CS2) was defined as studies in which the shed blood before and after CPB in the operative field and/or pump residual blood were collected and processed by a CS (with or without cardiotomy suction during CPB). This latter subgroup also included off-pump procedures in which all shed blood from incision to the end of the operation was washed by a CS and reinfused to patients. Sensitivity analysis was planned for study quality (Jadad score Ն3 vs Jadad score Ͻ3) and for blinded versus nonblinded trials. The P value for interaction across subgroups was used to determine whether the subgroups showed statistically different effect sizes.
Publication bias was explored through visual inspection of funnel plots in which the inverse of the estimated variance of the natural logarithm, of the adjusted relative risk, was plotted against the natural logarithm of the adjusted relative risk for each outcome. 29 Figure 1 outlines the search results. A total of 297 citations were screened. After reviewing the abstracts, 53 trials were retrieved for full-text review. Of these, 22 trials were excluded as they did not meet the preset inclusion criteria. Therefore, 2282 patients in 31 original trials provided data for this meta-analysis (Table  1) . 6 -18,19,21,22,30 -44 The median Jadad score was 2 (range, 1-5). Although, significant publication bias was not detected for the primary or secondary outcomes because funnel plots did not indicate that smaller negative studies were missing, it should be noted that the tests for detecting publication bias were generally underpowered, especially for the secondary outcomes when fewer trials adequately reported the outcomes of interest. There was no difference between CS and control groups, for age at baseline (WMD Ϫ0.34 yr, 95% CI: Ϫ1.05-0.37, P ϭ 0.35), and male gender (OR 1.10, 95% CI: 0.86 -1.41, P ϭ 0.43).
RESULTS
Transfusion Outcomes
Primary and secondary outcomes are summarized in Tables 2 and 3 . During cardiac surgery, the use of a CS significantly reduced the odds of exposure to any allogeneic blood product (OR 0.63, 95% CI: 0.43-0.94, P ϭ 0.02; Fig. 2 ) and exposure to allogeneic RBC transfusion (OR 0.60, 95% CI: 0.39 -0.92, P ϭ 0.02) compared with no CS (Fig. 3) . A CS also decreased the mean volume of the total allogeneic blood product transfused per patient (WMD Ϫ256 mL, 95% CI: Ϫ416 to Ϫ95, P ϭ 0.002) and showed a tendency to decrease the mean units of the RBCs transfused (WMD Ϫ0.43 u, 95% CI: Ϫ0.87 u to 0.01 u, P ϭ 0.06). A CS did not increase the number of patients transfused FFP (OR 1.16, 95% CI: 0.82-1.66, P ϭ 0.40; Fig. 4 ) or platelets Subgroup CS1 was defined as: CS was only used to process cardiotomy suction blood during CPB. Subgroup CS2 was defined as: the shed blood before and after CPB in the operative field and/or pump residual blood were collected and processed by CS (with or without cardiotomy suction during CPB), this subgroup also included off-pump procedure in which all shed blood from incision to the end of the operation was washed by CS and reinfused to patients. CCAB ϭ conventional coronary artery bypass; CPB ϭ cardiopulmonary bypass; CS ϭ cell saver; N ϭ number of patients; OPCAB ϭ off-pump coronary artery bypass.
(OR 0.90, 95% CI: 0.63-1.28, P ϭ 0.55; Fig. 5 ). Also, the mean units of FFP (WMD Ϫ0.08 u, 95% CI: Ϫ0.20 to 0.04, P ϭ 0.18) and platelets (WMD Ϫ0.36 u, 95% CI:
Ϫ0.98 u to 0.27, P ϭ 0.26) transfused were not significantly different for CS versus no CS. Although there was a significant heterogeneity across studies for the outcome of patients exposed to any blood product and patients exposed to RBCs, most of this was because of differences in the magnitude of reduction in odds rather than differences in direction of effect among the studies; however, the difference in the time period of a CS use may account for much of this heterogeneity (see Subanalyses section later). Similarly, there was also significant heterogeneity for the volume of blood products transfused and postoperative Hb values, which is to be expected given the likely differences in transfusion and hemostatic practices among institutions and differences in types of CS used (explored in Subanalysis section later). 
Clinical Complications
There was no difference between the patients receiving and not receiving CS in hospital mortality (OR 0.65, 95% CI: 0.25-1.68, P ϭ 0.37), postoperative stroke or transient ischemia attack (OR 0.59, 95% CI: 0.20 -1.76, P ϭ 0.34), acute myocardial infarction (OR 0.84, 95% CI: 0.38 -1.83, P ϭ 0.66), postoperative atrial fibrillation (OR 0.92, 95% CI: 0.69 -1.23, P ϭ 0.56), renal dysfunction (OR 0.86, 95% CI: 0.41-1.80, P ϭ 0.70), infection (OR 1.25, 95% CI: 0.75-2.10, P ϭ 0.39), or the number of patients requiring reoperation for bleeding (OR 0.61, 95% CI: 0.31-1.20, P ϭ 0.15; Table 2 ). Neurological outcomes were insufficiently reported for the combination of studies through meta-analysis.
Other Outcomes
There was no difference between CS and control groups in 24-h postoperative Hb (WMD 0.20 mg/dL, 95% CI: Ϫ0.26 to 0.65, P ϭ 0.39) and postoperative chest-tube drainage (WMD Ϫ14.9 mL, 95% CI: Ϫ61.8 to 31.9, P ϭ 0.53; Table 3 ). The use of a CS had no significant impact on the length of mechanical lung ventilation (WMD Ϫ0.13 h, 95% CI: Ϫ1.16 to 0.89, P ϭ 0.80), ICU length stay (WMD 0.00 days, 95% CI: Ϫ0.13 to 0.13, P ϭ 1.00), or hospital LOS (WMD Ϫ0.20, 95% CI: Ϫ0.54 to 0.15, P ϭ 0.26; Table 3 ).
QOL was measured in only one study, and there was no difference in the QOL scores between the CS and the control group either early (5 days) or late (3 mo) after surgery. 21 Two trials examined hospitalization costs. Because both studies did not report the standard deviation of the total costs, their results were not combined through meta-analysis. Klein et al. 22 found that the use of a CS in routine cardiac surgery resulted in higher mean total costs, but these did not reach statistical significance (US$ 17,785 vs 17,046, P ϭ 0.16). Similarly, Murphy et al. 15 reported that cell salvage was not associated with a significant increase in total cost (median difference, US$1015.9; 95% CI: US$2260 -206; P ϭ 0.11) compared with control.
Subgroup and Sensitivity Analyses
Analysis of a CS versus no CS for subgroups of patients undergoing off-pump versus on-pump surgery showed that a CS has similar effects on all outcomes regardless of whether the patients undergo heart surgery on or off the pump, except for a 24 h postoperative Hb that was improved to a greater degree with a CS in patients undergoing off-pump surgery than in patients undergoing on-pump surgery (WMD 1.0 vs 0.04 mg/dL for off-pump versus onpump, P value for interaction across subgroups Ͻ0.0001). Also, total blood volume transfused was improved to a greater degree with a CS in the studies of on-pump surgery (WMD Ϫ89 mL vs Ϫ318 mL for off-pump versus on-pump, P value for interaction across subgroups ϭ 0.06).
Subgroup analysis was also performed by the time period of CS use (CS1 versus CS2), where CS1 includes studies using a CS during CPB for cardiotomy suction blood only and CS2 includes studies using CS for shed and/or residual blood pre-CPB or post-CPB (with or without CS for cardiotomy suction blood). The magnitude of CS benefit was less in studies using CS1 than in studies using CS2 risk of exposure to any allogeneic blood product (35% increase in risk of transfusion with CS1 vs 51% reduction in risk of transfusion with CS2), risk of exposure to allogeneic RBC transfusion (13% increase in risk of RBC transfusion with CS1 vs 55% reduction in risk of RBC transfusion with CS2), and risk of exposure to allogeneic FFP transfusion (83% increase in risk of FFP transfusion with CS1 vs 11% reduction in risk of FFP transfusion with CS2; Table 4 ). Additionally, CS1 studies showed less benefit from CS with respect to the mean units of RBCs transfused (ϩ0.22 u with CS1 vs Ϫ0.66 u with CS2) and 24 h postoperative Hb (Ϫ0.3 mg/dL with CS vs ϩ 0.4 mg/dL with CS2; Table 5 ). The consistency of these findings across subgroup analyses supports the hypothesis that a CS used to process the shed blood throughout the operation (CS2) provides more benefit for blood conservation compared with a CS only used to process cardiotomy suction blood during CPB (CS1;  Tables 4 and 5 ). Furthermore, these results suggest that much of the heterogeneity of results observed across randomized trials of CS use is because of the differences in the time period of CS use.
Sensitivity analyses to explore whether the results varied between blinded and unblinded studies were not possible because only one trial was blinded. Sensitivity analysis of results by high versus low Jadad scores showed a significant relationship between study quality and effect size, whereby higher quality studies reported more conservative effects on reducing odds of patient exposure to RBCs (P value for interaction, 0.03).
DISCUSSION
Overall, this meta-analysis suggests that the intraoperative use of a CS apparatus during cardiac surgery decreased the odds of exposure to any allogeneic blood transfusion by 37% (95% CI: 43%-94%) and RBC transfusion by 40% (95% CI: 39%-92%). Meanwhile, CS use did not increase the number of patients transfused FFP or platelets. Postoperative complications and resource utilization did not differ significantly between patients using and not using a CS, although these outcomes were less commonly reported in clinical trials and lack of adequate power prevents definitive conclusions about the effect of a CS on clinically important outcomes, such as renal failure, stroke, and death. Some of the heterogeneity across trials in the magnitude of benefit provided by a CS can be explained by the differences in the time period of CS use, with CS used only during CPB for cardiotomy suction blood showing less benefit than CS used beyond CPB for shed blood and/or residual pump blood.
Our results contrast with prior meta-analyses on the use of a CS during surgery for blood conservation. In 1999, Heut et al. 45 published a meta-analysis on the use of a CS in orthopedic and cardiac surgical patients. For the cardiac group, they examined the risk of allogenic transfusion only and found a relative risk of allogeneic exposure of 0.85 (95% CI: of 0.79 -0.92). In 2006, Carless et al. 46 examined the use of a CS in all types of surgery to reduce blood transfusion. For the cardiac surgery subgroup (10 trials involving 798 patients), they found a relative risk for exposure to RBCs of 0.70 (95% CI: 0.56 -0.87), which is more than the result found in our meta-analysis including 31 randomized controlled trials (when we convert our results from odds ratio to relative risk, RR ϭ 0.80, 95% CI: 0.68 -0.95). The reduction in RBC units transfused was Ϫ0.64 u (Ϫ0.91 u to Ϫ0.39 u), suggesting a benefit with cell salvage in the Carless meta-analysis, which is more than our finding of reduction by 0.5 u (Ϫ0.98 u to 0 u) for RBCs. The results of Carless et al. suggest a greater benefit from cell salvage than was found in our study, likely because more recent trials published after 2006 have shown less benefit. It is noteworthy that several of the more recent trials used cell salvage during CPB only, and this supports the hypothesis that a CS applied throughout the operative period may be required to provide measurable impact. Finally, all previous meta-analysis included trials with a Subgroup CS1 was defined as: CS was only used to process cardiotomy suction blood during CPB. Subgroup CS2 was defined as: the shed blood before and after CPB in the operative field and/or pump residual blood were collected and processed by CS (with or without cardiotomy suction during CPB), this subgroup also included off-pump procedure in which all shed blood from incision to the end of the operation was washed by CS and reinfused to patients. AF ϭ atrial fibrillation; CI ϭ confidence interval; CS ϭ cell saver; FFP ϭ fresh frozen plasma; ICU ϭ intensive care unit; LOS ϭ length of stay; MI ϭ myocardial infarction; n ϭ number of patients; N ϭ number of trials; OR ϭ odds ratio; PLT ϭ platelet; POD ϭ postoperation day; pts ϭ patients; RBCs ϭ red blood cells; RF ϭ renal failure; TIA ϭ transient ischemia attack; WMD ϭ weighted mean difference.
washed and unwashed CS, whereas the present study included only trials of washed CS. Because recent studies have suggested that the use of a CS does not result in improvements in RBC transfusions but may increase FFP transfusions, 19, 21, 22 we planned to explore reasons for the differences among the estimates of benefit from a CS across the studies included in this meta-analysis. To determine the time period of CS use or the type of surgery affecting the estimates of benefit from a CS, we subgrouped the studies based on the type of surgery (on-pump versus off-pump) and the time period a CS was used (CS1-during CPB exclusively or CS2-before and after bypass with or without use during CPB). The results of these subanalyses suggest that the type of surgery (whether on-pump or off-pump) has no measurable impact on the benefits from a CS. However, the time period of CS use did have an impact on the magnitude of the benefits of a CS. When a CS was used only during CPB (CS1), FFP transfusions were increased over control, and the amount of reduction in any blood product transfused, RBCs, and mean units of RBCs transfused were less compared with the overall benefit shown when CS was applied throughout the surgery. In the CS2 group, the benefits on FFP transfusions, any blood product transfused, RBCs, and mean units of RBCs transfused were greater than the overall estimate of CS1 ϩ CS2 studies combined. This suggests that meta-analyses combining trials of CS use during CPB only (CS1, which is less effective) with trials of CS use beyond CPB or throughout the entire operative period (CS2, which is more effective) will provide a heterogeneous estimates of effect, with estimates of benefit that are more conservative than if the more effective CS2 is subanalyzed separately.
During CPB, blood collected from the cardiotomy suction contains high levels of cellular debris and lipid microparticulates, 47, 48 which have been shown in animal models to be associated with cerebral microembolization. 49 These previous animal studies demonstrated that when shed blood from the cardiotomy reservoir was processed with a CS device, the number of lipid-containing small arteriolar capillaries was significantly reduced compared with those when cardiotomy blood was returned unprocessed to the CPB reservoir. 50 Brain microembolization has been implicated as one mechanism for cognitive decline after cardiac surgery. 51 Two recent studies in the present review measured neurocognitive function. The results were not combined through meta-analysis because of Ϫ28 (Ϫ85 to 29) 30 0.33
Subgroup CS1 was defined as: CS was only used to process cardiotomy suction blood during CPB. Subgroup CS2 was defined as: the shed blood before and after CPB in the operative field and/or pump residual blood were collected and processed by CS (with or without cardiotomy suction during CPB), this subgroup also included off-pump procedure in which all shed blood from incision to the end of the operation was washed by CS and reinfused to patients. CI ϭ confidence interval; CS ϭ cell saver; FFP ϭ fresh frozen plasma; Hb ϭ hemoglobin; ICU ϭ intensive care unit; LOS ϭ length of stay; n ϭ number of patients; N ϭ number of trials; NA ϭ not available; PLT ϭ platelet; POD ϭ postoperation day; RBCs ϭ red blood cells; WMD ϭ weighted mean difference.
the different methods of postoperative measurement. Djaiani et al. 19 reported that cognitive dysfunction was present in 6% (95% CI: 1.3%-10.7%) of patients in the CS group and 15% (95% CI: 8%-22%) of patients in the control group, 6 wk after coronary bypass surgery (P ϭ 0.038). However, at 1 yr follow-up this difference was not sustained (19.0% vs 17.4% of patients had cognitive dysfunction at 1 yr in CS versus non-CS group, respectively). 52 Moreover, Rubens et al. 21 found no difference in the incidence of postoperative cognitive dysfunction between the CS and the control group (45.3% vs 39.0%, relative risk: 1.16, 95% CI: 0.86 -1.57 at 5 days postoperatively; 16.7% vs 15.9%, relative risk: 1.05, 95% CI: 0.58 -1.90 at 3 mo). The role of CS use in decreasing the early postoperative neurocognitive dysfunction in cardiac surgery is still uncertain and needs further research with long-term follow-up. There are several strengths and limitations associated with this study. Our comprehensive search strategy for randomized trials of all relevant outcomes, comparisons in any language, and the adherence to Quality of Reporting of Meta-analyses recommendations serves to increase confidence that this represents a complete summary of the best available evidence. The limitations include few trials reporting all pertinent outcomes (in particular, clinical outcomes other than transfusion requirements). Also, few trials reported sufficient detail to allow adequate assessment of the volume of blood salvaged with a CS and the type of cell-saving technique used. These shortcomings have implications for the risks and benefits associated with CS use at individual institutions. Furthermore, there was no research defining longterm clinical, economic, or QOL outcomes associated with CS use. The heterogeneity among the trials may be of concern, especially with respect to the heterogeneity associated with the study quality. For RBC exposure, lower quality studies estimated a larger risk reduction than for higher quality studies, and higher quality studies suggested more conservative effects on RBC units transfused than lower quality studies. These results imply that the lack of methodological rigor in the lower quality studies (i.e., lack of allocation concealment, lack of blinding, and incomplete follow-up of patients) may have allowed investigators to report more favorable effects on transfusions and provide compelling support for more robust methodology in future clinical trials to prevent biased observations of effect. Nevertheless, despite this limitation, it is important to note that the studies uniformly suggested reductions in transfusions but varied in their estimates of magnitude of effect rather than direction of effect. Additionally, some of the heterogeneity in the magnitude of impact of CS use across the trials was found to be because of the differing types of CS use (CS1 versus CS2). This suggests that trials applying a CS only during CPB (less effective) should be subanalyzed separately from CS applied pre-CPB, during CPB, and post-CPB (more effective) in future meta-analyses as the results may be dependent on the time periods of CS use.
Overall, current evidence suggests that the use of a CS reduces exposure to allogeneic blood products or RBC transfusion for patients undergoing cardiac surgery. Subanalyses suggest that a CS may be beneficial only when it is used for shed blood and/or residual blood or during the entire operative period. Processing cardiotomy suction blood with a CS only during CPB has no significant effect on blood conservation and increases FFP transfusion. Most importantly, the effect of a CS on important outcomes such as death, organ dysfunction, neurological function, QOL, and cost-effectiveness remain unproven.
